Relmada Therapeutics Inc’s recent filing unveils that its Chief Executive Officer TRAVERSA SERGIO acquired Company’s shares for reported $0.15 million on Sep 11 ’24. In the deal valued at $2.99 per share,51,407 shares were bought. As a result of this transaction, TRAVERSA SERGIO now holds 384,024 shares worth roughly $0.15 million.
Then, TRAVERSA SERGIO bought 55,579 shares, generating $150,619 in total proceeds. Upon buying the shares at $2.71, the Chief Executive Officer now owns 299,603 shares.
Before that, TRAVERSA SERGIO bought 33,014 shares. Relmada Therapeutics Inc shares valued at $90,788 were divested by the Chief Executive Officer at a price of $2.75 per share. As a result of the transaction, TRAVERSA SERGIO now holds 332,617 shares, worth roughly $0.13 million.
Mizuho downgraded its Relmada Therapeutics Inc [RLMD] rating to a Neutral from a an Outperform in a research note published on December 05, 2024; the price target was decreased to $1 from $23. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in mid September from “a Hold” to “a Buy”. Goldman also remained covering RLMD and has decreased its forecast on June 05, 2024 with a “Sell” recommendation from previously “Neutral” rating. Truist revised its rating on October 14, 2022. It rated RLMD as “a Hold” which previously was an “a Buy”.
Price Performance Review of RLMD
On Monday, Relmada Therapeutics Inc [NASDAQ:RLMD] saw its stock jump 4.60% to $0.38. Over the last five days, the stock has lost -2.37%. Relmada Therapeutics Inc shares have fallen nearly -90.83% since the year began. Nevertheless, the stocks have fallen -87.13% over the past one year. While a 52-week high of $7.22 was reached on 03/04/24, a 52-week low of $0.34 was recorded on 12/19/24. SMA at 50 days reached $2.4707, while 200 days put it at $3.3013.
Levels Of Support And Resistance For RLMD Stock
The 24-hour chart illustrates a support level at 0.3531, which if violated will result in even more drops to 0.3265. On the upside, there is a resistance level at 0.4031. A further resistance level may holdings at 0.4265. The Relative Strength Index (RSI) on the 14-day chart is 17.85, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0520, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.14%. Stochastics %K at 3.65% indicates the stock is a buying.
How much short interest is there in Relmada Therapeutics Inc?
A steep rise in short interest was recorded in Relmada Therapeutics Inc stocks on 2024-10-15, growing by 76086.0 shares to a total of 1.26 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 1.18 million shares. There was a rise of 6.06%, which implies that there is a positive sentiment for the stock.
